ERBB2 and cancer: The design of effective antibody-drug conjugates for cancer therapy necessitates the selection of an appropriate target, such as HER-2 (Najjar et al., 2022; Tarantino et al., 2022), a monoclonal antibody against the target, potent cytotoxic effector molecules and the linker of the monoclonal antibody to cytotoxic agents (Thomas et al., 2016).